Globe Newswire (Mon, 6-Jul 11:35 AM ET)
Market Chameleon (Mon, 6-Jul 3:07 AM ET)
Globe Newswire (Mon, 6-Jul 6:00 AM ET)
PRNewswire (Thu, 25-Jun 11:35 AM ET)
Scilex to List Dream Bowl I Meme Coin on Biconomy—Liquidity Opportunity for Shareholders Looms
Market Chameleon (Tue, 16-Jun 3:47 AM ET)
Globe Newswire (Tue, 16-Jun 7:45 AM ET)
Globe Newswire (Fri, 12-Jun 7:53 AM ET)
Globe Newswire (Thu, 4-Jun 9:00 AM ET)
Globe Newswire (Fri, 22-May 1:15 PM ET)
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Scilex Holding Company trades on the NASDAQ stock market under the symbol SCLX.
As of July 22, 2026, SCLX stock price declined to $7.41 with 31,708 million shares trading.
SCLX has a beta of 1.47, meaning it tends to be more sensitive to market movements. SCLX has a correlation of 0.02 to the broad based SPY ETF.
SCLX has a market cap of $52.11 million. This is considered a Micro Cap stock.
In the last 3 years, SCLX traded as high as $229.25 and as low as $3.60.
The top ETF exchange traded funds that SCLX belongs to (by Net Assets): VTI, VXF, IWC, AVTM, DFAU.
SCLX has underperformed the market in the last year with a price return of -13.8% while the SPY ETF gained +20.5%. However, in the short term, SCLX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +8.5% vs +6.8% return in SPY. But in the last 2 weeks, SCLX shares have been beat by the market, returning -25.4% compared to an SPY return of +0.3%.
SCLX support price is $7.18 and resistance is $8.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SCLX shares will trade within this expected range on the day.